ProMetic and Serono Sign a Development and Collaboration Agreement
Development revenues for ProMetic of up to £550,000 (approx. $C1.3M)
Montreal, Canada. ProMetic Life Sciences Inc. wholly owned subsidiary ProMetic Biosciences Ltd announced that it has signed a development and collaboration agreement with laboratories Serono S.A. to provide Serono access to ProMetic´s unique protein purification technology.
Serono will fund the development of an affinity adsorbent to isolate and purify a protein of interest to Serono. A Mimetic Ligand(TM) will be selected from ProMetic´s Intelligent Combinatorial Libraries and will be designed to enhance Serono´s already rigorous therapeutic purification procedures.
"We are thrilled that Serono, a world leader in recombinant products, has chosen ProMetic´s technology to further enhance its manufacturing and purification processes!, commented Pierre Laurin, President and CEO of ProMetic Life Sciences Inc. !This agreement confirms once again the establishment of ProMetic as a world leader in the plasma and recombinant protein purification market!.
Most read news
Organizations
Other news from the department business & finance
Get the analytics and lab tech industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.
Most read news
More news from our other portals
Last viewed contents
Xantos Biomedicine and QIAGEN AnnounceCo-Marketing Agreement for RNAi Library with High-Content Cellular Screening System
Closing in on mystery surrounding dangerous blood syndromes - Genetically driven MDS enabled by gene linked to metabolism and oxygen in cells
Long-COVID - all a question of genes? - New study results show possible risk factor
Beckman Coulter and Fujirebio enter into partnership - The goal is a patient-friendly, blood-based Alzheimer's disease test
Beta cells from stem cells: Potential for cell replacement therapy - Quality control with CD177 can help save lots of time, efforts and money
Clinical Reference Laboratory Inc to build European laboratory hub in UK
The evolution of cancer cells decoded - "Our vision is a new type of early cancer detection"
Protagen Deepens Cooperation With Bayer Schering Pharma
Seeing a diagnosis: How an eye test could aid Alzheimer's detection
C-mo Medical Solutions raises €4.1 million aiming to transform cough monitoring
New technique for testing drugs to treat cystic fibrosis and epilepsy